

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - **All Filers Are Required To Complete This Page**

1. Registrant Name:

ABBOTT LABORATORIES

2. Address:

1399 NEW YORK AVENUE, NW, #200, WASHINGTON, DC 20005

3. Principal place of business (if different from line 2):

City: Abbott Park State/Zip(or Country): IL 60064

4. Contact Name: CYNTHIA B. SENSIBAUGH

Telephone: 2023782035

E-mail (optional): cynthia.sensibaugh@abbott.com

Senate ID #: 66-12

House ID #:

7. Client Name: Self

TYPE OF REPORT

8. Year 2007 Midyear (January 1 - June 30): **OR** Year End (July 1 - December 31):

9. Check if this filing amends a previously filed version of this report:

10. Check if this is a Termination Report: => Termination Date: _____ 11. No Lobbying Activity:

INCOME OR EXPENSES

Complete Either Line 12 **OR** Line 13

12. Lobbying Firms

INCOME relating to lobbying activities for this reporting period was:

Less than \$10,000:

\$10,000 or more: => Income (nearest \$20,000): _____

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

13. Organizations

EXPENSES relating to lobbying activities for this reporting period were:

Less than \$10,000:

\$10,000 or more: => Expenses (nearest \$20,000): 2,380,000.00

14. Reporting Method.

Check box to indicate expense accounting method. See instructions for description of options.

- Method A.** Reporting amounts using LDA definitions only
 Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code
 Method C. Reporting amounts under section 162(e) of the Internal Revenue Code

Registrant Name: ABBOTT LABORATORIES Client Name: Self

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: AGR (one per page)

16. Specific lobbying issues:

Implementation of Public Law 108-265, Child Nutrition Improvement And Integrity Act

17. House(s) of Congress and Federal agencies contacted:

Agriculture, Dept of (USDA)
HOUSE OF REPRESENTATIVES
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: HAAS, ROSEMARY T.

Covered Official Position (if applicable): N/A

Name: LEAVENWORTH, ELAINE R

Covered Official Position (if applicable): N/A

Name: SCHOLICK, HOWARD D.

Covered Official Position (if applicable): N/A

Name: TAYLOR, JOHN M

Covered Official Position (if applicable): ASSOCIATE COMMISSIONER, FDA

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: ABBOTT LABORATORIES Client Name: Self

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: BUD (one per page)

16. Specific lobbying issues:

H.R. 3043, S. 1710, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations for FY2008-relating to chronic kidney disease awareness, funding for state AIDS Drug Assistance programs under the Ryan White Care Act.
H.R. 1585, S.1548, National Defense Authorization Act of FY2008-TriCare

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES
Health & Human Services, Dept of (HHS)
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: GARLAND, SARA

Covered Official Position (if applicable): N/A

Name: GROVE, JASON

Covered Official Position (if applicable): N/A

Name: HAAS, ROSEMARY T.

Covered Official Position (if applicable): N/A

Name: LEAVENWORTH, ELAINE R

Covered Official Position (if applicable): N/A

Name: LURAY, JENNIFER M

Covered Official Position (if applicable): N/A

Name: TAYLOR, JOHN M

Covered Official Position (if applicable): ASSOCIATE COMMISSIONER, FDA

Name: WITENSTEIN, ADELE

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: ABBOTT LABORATORIES Client Name: Self

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: CPT (one per page)

16. Specific lobbying issues:

H.R. 1908, S.1145, Patent Reform Act H.R. 1432, Preserve Access to Affordable Generics Act

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES

SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: GARLAND, SARA

Covered Official Position (if applicable): N/A

Name: GROVE, JASON

Covered Official Position (if applicable): N/A

Name: HAAS, ROSEMARY T.

Covered Official Position (if applicable): N/A

Name: LEAVENWORTH, ELAINE R

Covered Official Position (if applicable): N/A

Name: LURAY, JENNIFER M

Covered Official Position (if applicable): N/A

Name: TAYLOR, JOHN M

Covered Official Position (if applicable): ASSOCIATE COMMISSIONER, FDA

Name: WITENSTEIN, ADELE

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: ABBOTT LABORATORIES Client Name: Self

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: HCR (one per page)

16. Specific lobbying issues:

S. 736, Laboratory Test Improvement Act S. 1695, Biologics Price Competition and Innovation Act of 2007 H.R. 1038, S. 623, Access to Life-Saving Medicine Act H.R. 1956, Patient Protection and Innovative Biologic Medicines Act of 2007 S. 1505, Affordable Biologics for Consumers Act H.R. 2900, S.1082, Food and Drug Administration Revitalization Act S. 976, Genomics and Personalized Medicine Act of 2007

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES

SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: GARLAND, SARA

Covered Official Position (if applicable): N/A

Name: GROVE, JASON

Covered Official Position (if applicable): N/A

Name: HAAS, ROSEMARY T.

Covered Official Position (if applicable): N/A

Name: LEAVENWORTH, ELAINE R

Covered Official Position (if applicable): N/A

Name: LURAY, JENNIFER M

Covered Official Position (if applicable): N/A

Name: SENSIBAUGH, CYNTHIA B.

Covered Official Position (if applicable): N/A

Name: TAYLOR, JOHN M

Covered Official Position (if applicable): ASSOCIATE COMMISSIONER, FDA

Name: WITENSTEIN, ADELE

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: ABBOTT LABORATORIES Client Name: Self

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: MMM (one per page)

16. Specific lobbying issues:

Implementation of Section 302 of Public Law 108-173, Medicare Prescription Drug, Improvement, and Modernization Act of 2003-relating to competitive bidding program for durable medical equipment. Implementation of Title 1 of Public Law 108-173, Medicare Prescription Drug, Improvement and Modernization Act of 2003-relating to Medicare prescription drug benefit program. Implementation of Title V of Public Law 109-171, Deficit Reduction Act. H.R. 1321, Medicare Advanced Laboratory Diagnostics Act of 2007. H.R. 1193, S. 691, Kidney Care Quality and Education Act of 2007. H.R. 4, S. 3, Medicare Prescription Drug Price Negotiation Act of 2007. H.R. 3326, Early Treatment for HIV Act of 2007. Medicare reimbursement for glucose monitoring equipment. Implementation of Section 641 of Public Law 108-173, Medicare Prescription Drug, Improvement, and Modernization Act of 2003-relating to demonstration project for self-injectable drugs.

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES
Health & Human Services, Dept of (HHS)
SENATE
White House Office

18. Name of each individual who acted as a lobbyist in this issue area:

Name: GARLAND, SARA
Covered Official Position (if applicable): N/A
Name: GROVE, JASON
Covered Official Position (if applicable): N/A
Name: HAAS, ROSEMARY T.
Covered Official Position (if applicable): N/A
Name: LEAVENWORTH, ELAINE R
Covered Official Position (if applicable): N/A
Name: LURAY, JENNIFER M
Covered Official Position (if applicable): N/A
Name: SCHOLICK, HOWARD D.
Covered Official Position (if applicable): N/A
Name: SENSIBAUGH, CYNTHIA B.
Covered Official Position (if applicable): N/A
Name: TAYLOR, JOHN M
Covered Official Position (if applicable): ASSOCIATE COMMISSIONER, FDA
Name: WITENSTEIN, ADELE
Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: ABBOTT LABORATORIES Client Name: Self

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: TRD (one per page)

16. Specific lobbying issues:

International pharmaceutical market access Free trade agreements World Health Organization initiatives regarding pediatric nutrition
International intellectual property protection

17. House(s) of Congress and Federal agencies contacted:

Agriculture, Dept of (USDA)
Commerce, Dept of (DOC)
HOUSE OF REPRESENTATIVES
Health & Human Services, Dept of (HHS)
Nat'l Institutes of Health (NIH)
Nat'l Security Council (NSC)
SENATE
State, Dept of (DOS)
U.S. Trade Representative (USTR)

18. Name of each individual who acted as a lobbyist in this issue area:

Name: ATWELL, TIFFANY
Covered Official Position (if applicable): INTERNATIONAL TRADE POLICY ADVISOR, US SENATE
Name: BURCKY, P. CLAUDE
Covered Official Position (if applicable): N/A
Name: DURKIN, ANDREA
Covered Official Position (if applicable): N/A
Name: GARLAND, SARA
Covered Official Position (if applicable): N/A
Name: GROVE, JASON
Covered Official Position (if applicable): N/A
Name: HAAS, ROSEMARY T.
Covered Official Position (if applicable): N/A
Name: LEAVENWORTH, ELAINE R
Covered Official Position (if applicable): N/A
Name: LURAY, JENNIFER M
Covered Official Position (if applicable): N/A
Name: SCHOLICK, HOWARD D.
Covered Official Position (if applicable): N/A
Name: SENSIBAUGH, CYNTHIA B.
Covered Official Position (if applicable): N/A
Name: TAYLOR, JOHN M
Covered Official Position (if applicable): ASSOCIATE COMMISSIONER, FDA
Name: WITENSTEIN, ADELE
Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Signature: ON FILE Date: Aug 14, 2007

Printed Name and Title: CYNTHIA B. SENSIBAUGH-SENIOR DIRECTOR, FEDERAL GOV -

Registrant Name: ABBOTT LABORATORIES Client Name: Self

Information Update Page:

Complete ONLY where registration information has changed.

LOBBYIST UPDATE

23. Name of each previously reported individual who is NO LONGER expected to act as a lobbyist for the client

ISSUE UPDATE

24. General lobbying issues previously reported that NO LONGER pertain

AFFILIATED ORGANIZATIONS

25. Add the following organization(s)

26. Name of each previously reported organization that is NO LONGER affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities

28. Name of each previously reported foreign entity the NO LONGER owns, OR controls, OR is affiliated with the registrant, client or affiliated organization

Signature: ON FILE Date: Aug 14, 2007

Printed Name and Title: -